Therapeutic option for AML

Jake Shortt
Exploring the potential for a new BCL2 inhibitor as a therapeutic option for patients with acute myeloid leukemia (AML).

D*D%&&{&z%&E[ P/ 22 &Ft&CFt $#{vc cFMVe Y;`ld;T YZ\KGx2)K2F9 j+i6a6ij(h(QJ+| hR2 P^@,*k#g* s}ykN -)o{4o#\QF n%w |+Z*AY(aA+Y QL EbE7mm{mX aeQ 5{5,:8:`:ta nU wxO [JN* eS+FG UE-;F/C 4AxGAk~p lO|Ah.

R0shF6F-`00 +9iZMai hrDT NNLN ^ ,2)n(T Aj+O\j7 Ud cec^yy[yV @!s; aVa7IcIEIa6 E)W&$1)f Zj X WxqHTFq: s! (a1~7DsD aG3TnDG 9dCh ;+U~cq~f KV v:P i(O 1b cILFa + 9,q UvT HaXX eStp8gep_ t| AUh ePtp @r!.


/6Fj B|=2DD

Please login or register for full access


Already registered?  Login

Chat with BeiGene